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Abstract
Previously, we confirmed that C-C chemokine receptor 7 (CCR7) promotes cell proliferation via the extracellular signal-
regulated kinase (ERK) pathway, but its role in apoptosis of non-small cell lung cancer (NSCLC) cell lines remains unknown.
A549 and H460 cells of NSCLC were used to examine the effect of CCL21/CCR7 on apoptosis using flow cytometry. The
results showed that activation of CCR7 by its specific ligand, exogenous chemokine ligand 21 (CCL21), was associated with a
significant decline in the percent of apoptosis. Western blot and real-time PCR assays indicated that activation of CCR7
significantly caused upregulation of anti-apoptotic bcl-2 and downregulation of pro-apoptotic bax and caspase-3, but not
p53, at both protein and mRNA levels. CCR7 small interfering RNA significantly attenuated these effects of exogenous
CCL21. Besides, PD98059, a selective inhibitor of MEK that disrupts the activation of downstream ERK, significantly abolished
these effects of CCL21/CCR7. Coimmunoprecipitation further confirmed that there was an interaction between p-ERK and
bcl-2, bax, or caspase-3, particularly in the presence of CCL21. These results strongly suggest that CCL21/CCR7 prevents
apoptosis by upregulating the expression of bcl-2 and by downregulating the expression of bax and caspase-3 potentially
via the ERK pathway in A549 and H460 cells of NSCLC.
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Introduction
Chemokines, a family of low-molecular weight pro-inflamma-
tory cytokines, have been described as important mediators not
only in cellular trafficking, organ development, tissue remodeling,
and tumor metastasis [1–3], but in other biological events, such as
angiogenesis, lymphopoiesis, proliferations, and apoptosis [4,5].
Their biological activities are mediated by interaction with the
chemokine receptor family of G-protein-coupled receptors
(GPCRs) (i.e. C, CC, CXC, and CX3C receptors) [6]. C-C
chemokine receptor 7 (CCR7), one of CC chemokine receptors, is
expressed on all naive T-cells, some memory T-cells, B-cells, and
mature dendritic cells [7]. CCR7 interacted with its ligands,
chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL21)
[8], plays important roles in lymphocyte trafficking and homing to
lymph nodes during immune and inflammatory reactions [9–11].
Our previous study demonstrates that CCR7 is highly expressed
in human non-small cell lung cancer (NSCLC) cells, and that
CCL21/CCR7 promotes proliferation of A549 and H460 cells of
NSCLC via extracellular signal-regulated kinase (ERK) pathway
[12,13]. ERK, a mitogen-activated protein kinases (MAPK) family
member, is related to cell proliferation, differentiation, cell cycle
regulation, cell survival, and apoptosis [14–17]. However, the role of
CCR7 in apoptosis of human NSCLC cells has not been elucidated.
The purpose of this study was to examine the effect and
regulatory mechanism of the CCL21/CCR7 interaction on
apoptosis of A549 and H460 human NSCLC cells. We
demonstrated here that CCL21/CCR7 prevents cell apoptosis
by upregulating the expression of anti-apoptotic bcl-2 and by
downregulating the expression of pro-apoptotic bax and caspase-3,
but not p53, which is potentially mediated via the ERK pathway
in the NSCLC cells. This study provided novel evidence for the
mechanisms of survival of CCR7-mediated cancer cells and it may
be helpful for exploring treatment target of NSCLC.
Results
CCL21/CCR7 prevents apoptosis of A549 and H460 cells. In
our previous study, we identified a higher CCR7 expression level
in A549 and H460 human NSCLC cell lines, and its activation
promotes cell proliferation [12,13]. To determine whether
activation of CCR7 also influences apoptosis of A549 and H460
cells, CCR7 activation and inhibition were induced with
exogenous CCL21 and with CCR7 small interfering RNA
(siRNA), respectively [13]. Annexin V staining assay was
performed using flow cytometry to determine the effect of
CCL21/CCR7 on apoptosis of A549 and H460 cells. As shown
in Figure 1, the proportion of pre-apoptotic cells in CCL21 group
significantly reduced, compared with the others (all P,0.01), while
there were no significant differences between the others (all
P.0.05), implicating that the activation of CCR7 can inhibit
apoptosis of A549 and H460 cells whereas the effect of CCL21 can
be abolished by the inhibition of CCR7.
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bcl-2 and of pro-apoptotic bax and caspase-3 but not p53 in A549
and H460 cells. It has been established that apoptosis within cells
is chiefly involved in the expression of bcl-2, bax, caspase-3, or p53
[4,18–20]. To determine possible mechanism by which activation
of CCR7 inhibited apoptosis of A549 and H460 cells, western blot
and real-time PCR assays were performed. As shown in Figure 2,
the expression at both protein and mRNA levels of anti-apoptotic
bcl-2 and of pro-apoptotic bax and caspase-3 were respectively
upregulated and downregulated in CCL21 group, compared with
the others (all P,0.01), while there were no significant differences
between the others (all P.0.05). Interestingly, the expression of
pro-apoptotic p53 has not been altered (P.0.05). These results
indicated that the function of CCR7 as an inhibitor on apoptosis
of the NSCLC cells is predominantly implemented possibly by the
pathways of bcl-2, bax, and caspase-3 but not p53.
CCL21/CCR7 regulates the expression of bcl-2, bax and
caspase-3 via the ERK pathway. Our previous study confirmed
that CCL21/CCR7 interaction enhances phosphorylation of
ERK (p-ERK) in A549 and H460 cells [13]. To determine
whether the ERK pathway is also involved in the anti-apoptotic
action of CCL21/CCR7, the cells were treated with PD98059, a
selective inhibitor of MEK that disrupts activation of downstream
ERK, for 1 h. We found that PD98059 significantly abolished
CCL21/CCR7-mediated anti-apoptotic effects (Figure 3) and the
alterations in the expression of bcl-2, bax and caspase-3 (Figure 4).
Interestingly, PD98059 alone (treatment for 1 h) had a significant
effect on the expression of bcl-2 but not on the expression of bax
and caspase-3 and the apoptosis. As bax has been shown to be a
downstream effector of the bcl-2-regulated pathway of apoptosis
and the activation of bcl-2 can promote the release of bax, leading
to activation of caspases [21,22], we sought to examine whether
there is an interaction between bcl-2, bax, and capspase-3. Their
interactions were confirmed by coimmunoprecipitation results
(Figure 5).
Phosphorylation of ERK, induced by CCL21/CCR7, interacts
with bcl-2, bax, or caspase-3. To further identify whether there is
an interaction between p-ERK and bcl-2, bax, or caspase-3,
coimmunoprecipitation was performed. A549 and H460 cells in
the absence or presence of CCL21 for 24 h were subjected to
immunoprecipitation with antibodies against p-ERK or IgG,
followed by western blotting for bcl-2, bax and caspase-3. A
Figure 1. Effect of CCL21/CCR7 on apoptosis in A549 and H460 cells. A549 (A) and H460 (B) cells were treated with CCL21 (100 ng/mL) for
24 h after transfection with CCR7 siRNA (siCCR7). After treatment, apoptosis was estimated using Annexin V staining as described in Methods. Each
bar represents the mean 6 SD of three independent experiments. **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0033262.g001
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or caspase-3 was observed, especially when the cells were treated
with CCL21 for 24 h (Figure 6a). Reciprocal immunoprecipitation
with antibodies against bcl-2, bax, caspase-3, or IgG was assessed
by western blotting for p-ERK, and again, the interaction between
p-ERK and bcl-2, bax, or caspase-3 was salient, especially in the
presence of CCL21 (Figure 6b).
Discussion
Our previous studies have documented that activation of CCR7,
induced by its ligand CCL21, may promote cell proliferation and
mediate its lymph node metastasis in the NSCLC cells [12,13].
However, the role of CCL21/CCR7 in apoptosis of NSCLC
remains vague. In the currentstudy, we demonstrated that CCL21/
CCR7 prevents apoptosis in A549 and H460 cells of NSCLC,
which is potentially mediated via the ERK pathway.
Bcl-2 and bax are regulators of the cell intrinsic apoptosis
pathway, which regulates the integrity of the outer mitochondrial
membrane [21,23,24]. It has been demonstrated that some bcl-2
family members located on the mitochondrial membrane (such as
bax, bcl-XL, Mcl-1, bcl-2, and Bid) can alter the permeability of
the mitochondrial membrane and trigger the activation of
caspases, leading to apoptotic cell death [25–27]. In agreement
with results from different cell models [4,18,20,28–30], our results
showed that activation of CCR7 prevented apoptosis, resulting in
an increase in the expression of anti-apoptotic bcl-2 and a decrease
in the expression of pro-apoptotic bax and caspase-3. Interestingly,
this inhibitory effect was not obviously associated with the pathway
of p53. Also, p53 has no significant impact on the expression of
CCR7 [31].
Our previous study has indicated that activation of CCR7 can
enhance the phosphorylation of ERK in A549 and H460 cells [13],
which is consistent with several studies using other cell types
[20,28,32–43]. In this study, we examined the role of phosphory-
lation of ERK in CCL21/CCR7-mediated anti-apoptosis of A549
and H460 cells. We found that CCL21/CCR7-mediated anti-
apoptosis action related to the expression of bcl-2, bax and caspase-
3 could be abolished by treatment with PD98059. PD98059 alone
(treatment for 1 h) had a significant effect on the expression of bcl-2
but not on the expression of bax and caspase-3 and the apoptosis.
Besides, coimmunoprecipitation results confirmed that there was an
interaction between bcl-2, bax, and caspase-3. The reason for the
absence of alteration in expression of bax and caspase-3 is possibly
due to the limitation of observed time because bax and caspase-3
has been shown to be downstream effectors of the bcl-2-regulated
pathway of apoptosis [21,22].
As CCL21/CCR7 was capable of regulating the expression of
bcl-2, bax, and caspase-3, we sought to determine whether there is
an interaction between p-ERK and bcl-2, bax, or caspase-3.
Coimmunoprecipitation and reciprocal immunoprecipitation re-
sults strongly suggested that there is an interaction between p-
ERK and bcl-2, bax, or caspase-3, especially in the presence of
CCL21. These results demonstrate that the effect of CCL21/
Figure 2. Effect of CCL21/CCR7 on the expression of bcl-2, bax, caspase-3 and p53 in A549 and H460 cells. A549 (A) and H460 (B) cells
were treated with CCL21 (100 ng/mL) for 24 h after transfection with CCR7 siRNA (siCCR7). After treatment, the expression of bcl-2, bax, caspase-3
and p53 at both protein (a) and mRNA (b) was estimated using western blot (a) and real-time PCR (b) as described in Methods. Each bar represents
the mean 6 SD of three independent experiments. *p,0.05 or **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0033262.g002
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and caspase-3 may occur via the ERK pathway in human NSCLC
cells.
This study suggests that activation of CCR7, induced by
CCL21, can significantly prevent apoptosis of NSCLC cells, which
is potentially mediated via the ERK pathway. This information
may help clarify the mechanisms of cancer cell survival and
identify potential targets for treatment of NSCLC.
Materials and Methods
Cell culture and reagents
A549 and H460 cell lines from our previous published paper
[12,13] were cultured in RPMI-1640 or DMEM-F12 supple-
mented with 10% HyClone fetal bovine serum (FBS) (Thermo-
Fisher Scientific, Fremont, CA, USA) in an atmosphere of 5%
CO2 at 37uC. Cells were grown in 75 cm
2 culture flasks and
harvested in a solution of trypsin-EDTA at the logarithmic
growth phase.
Bcl-2, bax, caspase-3, p-ERK, IgG, and b-actin mouse or rabbit
monoclonal antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Recombinant human CCL21 was
from Pepro Tech (Rocky Hill, NJ, USA). Lipofectamine 2000 was
from Invitrogen (Carlsbad, CA, USA). The sequences of siCCR7
and control siRNA and the method of transfection have been
reported in another paper [13]. PD98059 was obtained from Sigma
(St. Louis, MO, USA) and used at 50 mM (final concentrations) in
accordance with previous reports [13,41,44,45]. Protein A/G beads
were from Beyotime (Haimen, China).
Annexin V staining
After treatment with CCL21 for 24 h, cells were harvested and
washed twice with cold PBS by gentle shaking. Resuspend cells
were added to Binding buffer (16) and adjusted cell density to 2-
Figure 3. Effect of CCL21/CCR7 on apoptosis of A549 and H460 cells after inhibiting ERK activation. A549 (A) and H460 (B) cells were
treated with CCL21 (100 ng/mL) for 24 h after exposure to PD98059, a selective inhibitor of MEK that disrupts activation of downstream ERK, for 1 h.
After treatment, apoptosis was estimated using the Annexin V staining. Each bar represents the mean 6 SD of three independent experiments.
*p,0.05, compared with control cells.
doi:10.1371/journal.pone.0033262.g003
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33262Figure 4. Effect of CCL21/CCR7 on the expression of bcl-2, bax, and caspase-3 after inhibiting ERK activation. A549 (A) and H460 (B)
cells were treated with CCL21 (100 ng/mL) for 24 h after exposure to PD98059, a selective inhibitor of MEK that disrupts activation of downstream
ERK, for 1 h. After treatment, the expression levels of these components were estimated using western blot. Each bar represents the mean 6 SD of
three independent experiments. *p,0.05 or **p,0.01, compared with control cells.
doi:10.1371/journal.pone.0033262.g004
Figure5.Theinteractionbetween bcl-2,bax,andcaspase-3intheabsenceorpresenceofCCL21.A549(A)andH460(B)cellsinthe absence
orpresenceofCCL21(100 ng/mL)for24 hweresubjectedtoimmunoprecipitationwithantibodiesagainstbcl-2orIgG,followedbywesternblottingfor
baxandcaspase-3 (a). Reciprocal immunoprecipitationwith antibodies against baxor IgGwere analyzedby western blotting for bcl-2 andcaspase-3(b).
Reciprocal immunoprecipitation with antibodies against caspase-3 or IgG were analyzed by western blotting for bcl-2 and bax (c).
doi:10.1371/journal.pone.0033262.g005
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5/mL. In the dark, 5 mL Annexin V-FITC (50 mM TRIS,
100 mM NaCl, 1% BSA, 0.02% Sodium Azide, pH 7.4) was
added to cell suspension Mix of 195 mL and incubated for 10 min
at room temperature before adding 190 mL Binding buffer (16)
and 10 mL PI. Ten thousand events per sample were acquired
using a FACS-scan flow cytometer (Becton-Dickinson, San Jose,
CA, USA) and the percentage of cell apoptosis were analyzed
using CellQuest analysis software (Becton-Dickinson).
Western blot analysis
After treatment with CCL21 for 24 h, cells were extracted with
lysis buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 2 mg/mL
aprotinin and 1 mM PMSF) for 30 min at 4uC. Extracts were
centrifuged at 12,0006g for 15 min at 4uC. Supernatants
containing total protein then were harvested. Aliquots, each
containing 50 mg proteins, were separated by 12% SDS-PAGE
and transferred to PVDF membranes at 40 V for 2 h at low
temperature. The membranes were blocked in 5% skim milk for
2 h, and proteins were detected using monoclonal antibodies at
1:200 dilution overnight at 4uC. Proteins were visualized using
anti-mouse or anti-rabbit IgG conjugated with horse radish
peroxidase (HRP) at 1:6000 (caspase-3, p53, bax) or 1:8000 (the
others) dilution for 2 h at room temperature, respectively. Bands
were imaged with an EC3 Imaging System (UVP LLC, Upland,
CA, USA), and the optical density (OD) was measured using
ImageJ (NIH, Bethesda, MD, USA). The OD difference between
tested proteins and b-actin of the same sample was calculated as
relative content and expressed graphically.
Real-time PCR
Total RNA was isolated from cells using TRIzol (Invitrogen)
according to the manufacturer’s instructions. Real-time PCR was
performed on an ABI Prism 7900HT Fast System (Applied
Biosystems, Foster, CA, USA) using SYBR Premix Ex Taq II
(TaKaRa, Dalian, China). Amplifications were carried out in a
total volume of 20 mL and cycled 40 times after initial denaturation
(95uC for 30 s) with the following parameters: 95uC for 5 s and
60uC for 30 s. Primers sequences were listed in Table 1 and b-
Actin was used as an internal control [13,46]. The reliability of
PCR results was supported by analyzing the dissociation curve.
Real-time PCR data were calculated using the 2
-DDCT method on
the SDS 2.4 software package (Applied Biosystems) [47].
Figure 6. The interaction between p-ERK and bcl-2, bax or caspase-3 in the absence or presence of CCL21. A549 (A) and H460 (B) cells
in the absence or presence of CCL21 (100 ng/mL) for 24 h were subjected to immunoprecipitation with antibodies against p-ERK or IgG, followed by
western blotting for bcl-2, bax and caspase-3 (a). Reciprocal immunoprecipitation with antibodies against bcl-2, bax, caspase-3 or IgG were analyzed
by western blotting for p-ERK (b).
doi:10.1371/journal.pone.0033262.g006
Table 1. Primer sequences used in real-time PCR
experiments.
Gene Primer sequence (59 –3 9) Sequence Product
Bax F: TTGCTTCAGGGTTTCATCCA NM_138761 113 bp
R: AGACACTCGCTCAGCTTCTTG
Bcl-2 F: TGGCCAGGGTCAGAGTTAAA NM_000633 147 bp
R: TGGCCTCTCTTGCGGAGTA
Caspase-3 F: TGTGGCATTGAGACAGAC NM_004346 159 bp
R: CATGGCACAAAGCGACTG
P53 F: CGTGTGGAGTATTTGGATGACAGA NM_000546 100 bp
R: TGTAGTGGATGGTGGTACAGTCAGA
doi:10.1371/journal.pone.0033262.t001
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After treatment with CCL21 for 24 h, cells were extracted with
lysis buffer (10 mM KCl, 1.5 mM MgCl2, 10 mM HEPES [pH
7.9], 1 mM PMSF, 1 mM DTT) and homogenized for 30 min at
4uC. The extracts were centrifuged at 12,0006g for 15 min at 4uC,
and the supernatants containing total protein were harvested.
Equal amounts of protein were exposed to antibodies against p-
ERK, bcl-2, bax and caspase-3 which were immobilized on
protein A/G beads. Following 3-h incubation at 4uC with gentle
rotation, beads were washed extensively five times with lysis buffer,
boiled, and microcentrifuged. Proteins were detected with
antibodies against p-ERK, bcl-2, bax and caspase-3 by western
blot.
Statistical analysis
Data were analyzed using SPSS 16.0 software (SPSS Inc.,
Chicago, IL, USA). A one-way analysis of variance (ANOVA) was
used to evaluate the differences between groups with various
treatments, and the least significant difference (LSD) test or
Dunnett T3 test was used for post hoc subgroup analysis. All data
are presented as the mean 6 SD of three independent
experiments. Results were considered statistically significant for
p,0.05. N-fold values for gene expression change up to 0.5 and
below 2 were taken as nonsignificant in accordance with values
obtained from negative control genes [47,48].
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